EHA 2020: Latest advances in Roche's CD20xCD3 dual-specific antibody glofitamab treatment for lymphoma

At the 25th annual meeting of the European Society of Hematology, Roche announced the latest data on its CD20xCD3 T-cell bispecific antibody glofitamab (formerly known as CD20-TCB) for patients with recurrent or refractive non-Hodgkin lymphoma (NHL)Glofitamab is a CD20xCD3 T-cell bispecific antibody designed to target CD20 and CD3 on the surface of B cellsGlofitamab is based on a novel form of structure, called "2:1", which refers to two "Fab" areas combined with CD20 and one "Fab" area combined with CD3The latest results from Roche's 2:1 T-cell bispecific antibodies (Photo: Roche's Official Website) glofitamab's Phase I Dose IncreaseNP30179 Study (NCT030756966666) show that patients with invasive and inert lymphoma received a long-lasting full response (CRs) from patients treated with invasive and inert lymphoma after three previous treatmentsIn the group inggroup of 0.6mg, the CR rate was 30.9% (38/123) for invasive NHL patients, 45.5% (56/123) overall remission rate (ORR), and for inert NHL patients, the CR rate was 52.2% (12/23) and the ORR was 65.2% (15/23)In the group of 10mg, the CR rate was 34.1% (29/85) for invasive NHL patients, 49.4% (42/85) for THE ORR, and 50.0% (9/18) for inert NHL patients and 66.7% (12/18) for INert NHL patientsDr Levi Garraway, Roche's chief medical officer and head of global product development, said: "Non-Hodgkin's lymphoma, such as diffuse large B-cell lymphoma, can pose significant treatment challenges, especially in a large number of patients who are at risk of relapseWe are encouraged by these early results and support the potential of glofitamab for patients who have previously failed multiple treatments and are in urgent need of new treatment options"